TMIGD3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2060202	0.63	8/20
SCHEMBL2060224	0.50	8/20
SCHEMBL1286288	0.64	6/20
SCHEMBL1286253	0.64	6/20
SCHEMBL2060237	0.58	6/20
SCHEMBL1224373	0.55	6/20
SCHEMBL1225047	0.49	6/20
SCHEMBL2060539	0.48	6/20
SCHEMBL1401990	0.48	6/20
SCHEMBL458946	0.77	5/20
SCHEMBL987009	0.64	5/20
SCHEMBL986631	0.63	5/20
SCHEMBL987008	0.63	5/20
SCHEMBL1286257	0.63	5/20
SCHEMBL1971997	0.62	5/20
SCHEMBL2332500	0.59	5/20
SCHEMBL1970640	0.57	5/20
SCHEMBL1145750	0.54	5/20
SCHEMBL239273	0.54	5/20
SCHEMBL1973000	0.54	5/20

Clinical trials — most relevant to TMIGD3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
co Ihibtory Receptor in Preeclampsia	PHASE4	UNKNOWN
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision	PHASE3	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer	PHASE1/PHASE2	COMPLETED
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma	PHASE2	UNKNOWN
Effects of Vitamin D Supplementation on Muscle Protein Synthesis	PHASE2	COMPLETED
A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma	PHASE1	COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis	EARLY_PHASE1	UNKNOWN
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors	nan	NOT_YET_RECRUITING
Study of Constitutional Platelet Disease	nan	UNKNOWN
Exosomal microRNAs as a Biomarker in Panic Disorder and in Response to CBT	nan	UNKNOWN
DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA	nan	COMPLETED
RAFTLIN-1 Levels in Axial Spondyloarthritis and Psoriatic Arthritis	nan	COMPLETED
Can the Risk for AMD be Modulated?	nan	ACTIVE_NOT_RECRUITING
Genetic Analysis of Hereditary Disorders of Hearing and Balance	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Efferocytosis and Genomic Polymorphism in Autoimmune Diseases	nan	UNKNOWN
Evaluation of CEMIP in Pancreatic Cancer	nan	UNKNOWN
Autophagy Bladder Cancer	nan	UNKNOWN
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Evaluation of Serum Gasdermin D Level As a Potential Biomarker of Disease Activity in Vitiligo Patients	nan	UNKNOWN
Mapping Novel Disease Genes for Dilated Cardiomyopathy	nan	COMPLETED
Immune Cell Response to Stimuli	nan	RECRUITING
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.	nan	UNKNOWN
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study)	nan	COMPLETED
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study	nan	RECRUITING
Association of Nutrition and T Cell Immune Activity With Disease Progression in Nontuberculous Mycobacterial Pulmonary Disease	nan	NOT_YET_RECRUITING
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others	nan	RECRUITING
Differential Expression of CD200 in B-chronic Lymphoproliferative Disorders by Multicolour Flow Cytometry	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TMIGD3 binder may also engage these)

Protein	Name	Similarity
G3X8R9	—	0.986	G3X8R9 →
Q1ERP8	—	0.972	Q1ERP8 →
A5D7B2	—	0.972	A5D7B2 →
Q5T2D2	—	0.969	Q5T2D2 →
Q68D85	—	0.968	Q68D85 →
Q9H106	—	0.968	Q9H106 →
Q2LA85	—	0.968	Q2LA85 →
P31995	—	0.966	P31995 →
Q3LRV9	—	0.965	Q3LRV9 →
CD79B	B-cell antigen receptor complex-associated protein beta chain	0.965	landscape →
Q2TB54	—	0.964	Q2TB54 →
P15530	—	0.964	P15530 →
O88875	—	0.964	O88875 →
Q63994	—	0.964	Q63994 →
Q6SJQ5	—	0.963	Q6SJQ5 →
Q9JL59	—	0.963	Q9JL59 →
A4KWA5	—	0.962	A4KWA5 →
Q6UXG3	—	0.962	Q6UXG3 →
Q5RFR2	—	0.962	Q5RFR2 →
Q02242	—	0.962	Q02242 →
O95944	—	0.960	O95944 →
Q8BG84	—	0.960	Q8BG84 →
Q8WVN6	—	0.960	Q8WVN6 →
O95971	—	0.959	O95971 →
Q2YFS1	—	0.959	Q2YFS1 →
P0CAN6	—	0.959	P0CAN6 →
Q6TYI6	—	0.958	Q6TYI6 →
KLRK1	NKG2-D type II integral membrane protein (Kil	0.958	landscape →
O95727	—	0.958	O95727 →
P0C1X9	—	0.958	P0C1X9 →